NCT03955315View on ClinicalTrials.gov

Study to Evaluate the Safety and Preliminary Efficacy of IDCT, a Treatment for Symptomatic Lumbar Disc Degeneration

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

May 23, 2019

Primary Completion Date

February 1, 2022

Study Completion Date

November 28, 2022

Conditions
Degenerative Disc Disease
Interventions
BIOLOGICAL

IDCT

Discogenic Cells + Sodium Hyaluronate Vehicle

PROCEDURE

Sham

Needle puncture under the muscular layer in front of the intervertebral disc

Trial Locations (6)

260-8670

Chiba University Hospital, Chuo-ku

259-1193

Tokai University Hospital, Isehara

514-8507

Mie University Hospital, Tsu

466-8550

Nagoya university hospital, Shōwaku

565-0871

Osaka University Hospital, Suita

409-3898

University of Yamanashi Hospital, Chūō

Sponsors

Lead Sponsor

DiscGenics, Inc.
All Listed Sponsors
lead

DiscGenics, Inc.

INDUSTRY

NCT03955315 - Study to Evaluate the Safety and Preliminary Efficacy of IDCT, a Treatment for Symptomatic Lumbar Disc Degeneration | Biotech Hunter | Biotech Hunter